Contribution of Trastuzumab to the Prognostic Improvement of HER2-positive Early Breast Cancer in Spain. An Estimation of Life Years and Disease-Free Life Years Gained Since Its Approval
Oncotarget - United States
doi 10.18632/oncotarget.27039
Full Text
Open PDFAbstract
Available in full text
Date
June 17, 2019
Authors
Unknown
Publisher
Impact Journals, LLC
